Correlate of immune protection against HSV-1 genital disease in vaccinated women

Journal of Infectious Diseases

Volumn 209, Issue 6, 2014, Pages 828-836

  Belshe, Robert B ^a   Heineman, Thomas C ^b   Bernstein, David I ^c   Bellamy, Abbie R ^d   Ewell, Marian ^d   Van Der Most, Robbert ^b   Deal, Carolyn D ^e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d EMMES CORPORATION   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

HSV vaccine; protective antibodies; vaccine efficacy

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN D; HERPES VACCINE; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMORAL IMMUNITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HSV VACCINE; PROTECTIVE ANTIBODIES; VACCINE EFFICACY;

ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CYTOKINES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HUMANS; PROSPECTIVE STUDIES;

EID: 84895772099     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit651     Document Type: Article

References (10)

1. Belshe RB, Leone PA, Bernstein DI, et al. for the Herpevac Trial for Women. Efficacy results of a trial of a herpes simplex vaccine. New Engl J Med 2012; 366:34-43.
2. Bernstein DI, Bellamy AR, Hook EW III, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 2013; 56:344-51.
3. Parsons LS. Performing a 1:N Case Control Match on Propensity Score. Proceedings of the Twenty Ninth Annual SAS Users Group International Conference, Cary, NC: SAS Institute Inc., 2004.
4. Ashley R, Cent A, Maggs V, Nahmias A, Corey L. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 1991; 115:520-6.
5. Maecker HT, Maino VC, Picker LJ. Immunofluorescence analysis of T-cell responses in health and disease. J Clin Immunol 2000; 20:391-9.
6. Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206:1280-90.
7. Ashley RL, Crisostomo FM, Doss M, et al. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine. J Infect Dis 1998; 178:1-7.
8. Stanberry LR, Spruance SL, Cunningham AL, et al. for the Glaxo- SmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D - adjuvant vaccine to prevent genital herpes. New Engl J Med 2002; 347:1652-61.
9. Corey L, Langenberg AGM, Sekulovich RE, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection. JAMA 1999; 282:331-40.
10. Kohl S, Charlebois ED, Sigouroundinia M, et al. Limited antibodydependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J Infect Dis 2000; 181:335-9.